Application

Immunofluorescence Analysis: A 1:100 dilution from a representative lot detected GFAP in human brain and rat brain tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected GFAP in C6 glioblastoma cells and primary cultures of rat glial precursor cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected GFAP in rat brain and human brain tissue sections.

Anti-GFAP, clone 2E8, ZooMAb, Cat. No. ZRB2383, is a recombinant Rabbit Monoclonal Antibody that specifically targets Glial fibrillary acidic protein (GFAP) and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), Immunfluorescence, and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 11 amino acids from the C-terminal region of human Glial fibrilary acidic protein (GFAP).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 2E8 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Glial fibrilary acidic protein (GFAP). It targets an epitope with in 11 amino acids from the C-terminal region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Glial fibrillary acidic protein (UniProt: P14136; also known as GFAP) is encoded by the GFAP gene (Gene ID: 2670) in human. GFAP is a class-III intermediate filament that serves as a cell-specific marker that can distinguish astrocytes from other glial cells. GFAP is not detected outside the central nervous system. It is expressed in cells that lack fibronectin. GFAP is a good marker of astroglial injury where its levels are consistently upregulated. GFAP levels are also shown to be upregulated with age in rodents and humans. Hence, it can serve as a surrogate marker of aging in the brain. GFAP has a relatively slow metabolic turnover rate, which is consistent with its structural role. GFAP is composed of three distinct regions: an N-terminal head region, a central ROD region, and a C-terminal tail region. The ROD regions are highly conserved among intermediate filament proteins. However, the size and amino acid sequences of the head and tail regions can vary widely. Three different isoforms of GFAP have been described that are produced by alternative splicing. Mutations in GFAP gene are known to cause Alexander disease that is characterized by progressive failure of central myelination, usually leading to death within the first decade. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.